Cross Country Healthcare Receives HSR Clearance for Knox Lane Acquisition
CCRN sits 78% above its 52-week low of $7.43 on elevated volume (1.9× avg).
Summary
Cross Country Healthcare announced that the HSR waiting period for its acquisition by Knox Lane has expired, satisfying a major closing condition for the $13.25 per share merger.
Key Events · M&A and Partnerships · CCRN
-
HSR Waiting Period Expired
The Hart-Scott-Rodino Antitrust Improvements Act waiting period for the merger and the related locums business sale expired on June 22, 2026.
-
Major Closing Condition Met
This regulatory clearance satisfies a key condition for the all-cash acquisition by Knox Lane to proceed, reducing deal risk.
-
Merger Expected Q3 2026
The acquisition, valued at $13.25 per share, is still expected to close in the third quarter of 2026.
-
Shareholder Vote Scheduled
A special meeting for shareholders to approve the merger is set for July 16, 2026.
Analysis · CCRN · Trade & Services
The expiration of the Hart-Scott-Rodino (HSR) waiting period removes a significant regulatory hurdle for the previously announced acquisition by Knox Lane. This brings the company closer to the expected Q3 2026 closing, reducing deal uncertainty for shareholders ahead of the July 16th vote.
At the time of this filing, CCRN was trading at $13.21 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $425.5M. The 52-week trading range was $7.43 to $14.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.